Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CTAD 2023: Roche’s Trontinemab Shows Rapid, Deep Amyloid Clearance Lacking From Gantenerumab

Ongoing Study Will Expand Before Next Trial Begins

Executive Summary

The first clinical trial results for Roche’s brain shuttle technology in Alzheimer’s patients showed that trontinemab cleared more amyloid and at a faster pace than its failed predecessor gantenerumab. 

You may also be interested in...



Pharma CEO Teresa Graham Talks About Roche’s Growth Momentum

Scrip spoke with Roche Pharmaceuticals CEO Teresa Graham about efforts to boost product sales, build out the drug development portfolio and return the company to revenue growth.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: CEOs on global tensions; Roche’s new Alzheimer's contender; Sanofi eyes external deals; investors’ reactions to clinical data; and Korean licensing pitfalls

How Roche Plans To Stay Ahead In MS And Catch Up In Alzheimer’s

Neuroscience is increasingly a focus for the Swiss pharma giant, and it believes it can stay ahead in multiple sclerosis with fenebrutinib, while making up lost ground in with two key candidates in Alzheimer’s disease.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel